Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$1.2 million.

  • SAB Biotherapeutics' Cash from Financing Activities rose 25123.21% to $168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.6 million, marking a year-over-year increase of 154.44%. This contributed to the annual value of -$1.2 million for FY2024, which is 101.76% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Cash from Financing Activities stood at -$1.2 million for FY2024, which was down 101.76% from $66.8 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Cash from Financing Activities high stood at $66.8 million for FY2023, and its period low was -$1.2 million during FY2024.
  • In the last 3 years, SAB Biotherapeutics' Cash from Financing Activities had a median value of $1.1 million in 2022 and averaged $22.2 million.
  • In the last 5 years, SAB Biotherapeutics' Cash from Financing Activities soared by 6,250.81% in 2023 and then slumped by 101.76% in 2024.
  • SAB Biotherapeutics' Cash from Financing Activities (Yearly) stood at $9.0 million in 2020, then skyrocketed by 299.58% to $35.9 million in 2021, then crashed by 97.07% to $1.1 million in 2022, then skyrocketed by 6,250.81% to $66.8 million in 2023, then slumped by 101.76% to -$1.2 million in 2024.